Working… Menu

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03761849
Recruitment Status : Terminated (Based on the independent Data Monitoring Committee's recommendation that all dosing be stopped and patients continue to be followed for safety and efficacy outcomes as per protocol, without study drug administration from 22 March 2021.)
First Posted : December 3, 2018
Last Update Posted : May 13, 2021
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : March 26, 2021
Actual Study Completion Date : March 26, 2021